在接受冠状动脉动图的高风险患者中,埃达拉在预防对比诱导脏病的有效性:一项随机双盲试验
Azam Esmailnejad1,2, Sepideh Zununi Vahed2, Seyyedeh Mina Hejazian2
1Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Pharmacology research & perspectives
|July 3, 2024
概括
抗氧化剂埃达拉在接受冠状动脉血管造影的高风险患者中显示出减少对比诱发性病 (CIN) 的趋势. 虽然在统计学上不显著,但需要进一步的研究来确认其在预防CIN方面的潜在益处.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对比诱导性脏病 (CIN) 是对比介质在血管造影干预中使用后的一种严重并发症.
- 目前,对于CIN.没有确定的预防疗法.
- 高风险患者,特别是患有慢性病的患者,容易感染CIN.
研究的目的:
- 评估抗氧化剂埃达拉在预防慢性脏病 (CKD) 3-4期冠状动脉血管造影的患者中CIN的疗效.
- 评估单剂埃达拉对高风险人群中CIN发病率的影响.
主要方法:
- 一个单中心,双盲,随机对照试验,涉及90名符合条件的CKD第3-4期患者.
- 患者被随机分配,在冠状动脉血管检查前1小时接受埃达拉 (60mg/ 1L盐液) 或安慰剂输液.
- 两组都接受了标准的静脉注射水分;CIN被定义为手术后120小时血清肌氨酸增加25%.
主要成果:
- CIN的总体发生率为5.5%.
- 干预组 (edaravone) 的CIN率为2.2%,而对照组 (安慰剂) 的CIN率为8.9%.
- 使用埃达拉观察到的CIN发病率的减少在统计学上并不显著.
结论:
- 在对比剂之前服用单剂量埃达拉可能会降低高危患者的CIN发病率.
- 需要进行更大规模的研究来证实埃达拉对预防CIN的统计学意义和临床效用.
- 埃达拉代表了一种潜在的治疗策略,需要进一步研究如何管理CIN风险.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
486
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
486
01:22Dose-Response Relationship: Potency and Efficacy
4.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.3K
01:26Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
01:22Heart Failure Drugs: Diuretics
362
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K